Cargando…
Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature
BACKGROUND: Anti-leucine-rich glioma-inactivated 1 encephalitis is a newly emerged entity characterized by frequent faciobrachial dystonic seizures and a wide spectrum of subacute clinical symptoms such as other seizure types, mood and behavioral changes, and memory loss. We should be aware of diffe...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644483/ https://www.ncbi.nlm.nih.gov/pubmed/36348436 http://dx.doi.org/10.1186/s13256-022-03650-x |
_version_ | 1784826751374852096 |
---|---|
author | Karvigh, Sanaz Ahmadi Salehizadeh, Saeideh Vahabizad, Fahimeh |
author_facet | Karvigh, Sanaz Ahmadi Salehizadeh, Saeideh Vahabizad, Fahimeh |
author_sort | Karvigh, Sanaz Ahmadi |
collection | PubMed |
description | BACKGROUND: Anti-leucine-rich glioma-inactivated 1 encephalitis is a newly emerged entity characterized by frequent faciobrachial dystonic seizures and a wide spectrum of subacute clinical symptoms such as other seizure types, mood and behavioral changes, and memory loss. We should be aware of differentiating this diagnosis from psychogenic nonepileptic seizures. Mesial temporal, limbic structures, and basal ganglia are the most commonly involved regions. CASE PRESENTATION: Here we review the available data, and report on two young Iranian (White) females, 24 and 18 years old, who represent distinct aspects of the disease. The clinical presentation and degree of tissue involvement varies to some extent in the two reported cases. Case 1 had prominent neuropsychiatric symptoms and suffered from frequent faciobrachial dystonic seizures with more significant basal ganglia involvement, whereas case 2 suffered from severe memory decline and dialeptic seizures along with mesial temporal involvement. Symptoms were refractory to usual treatment and prompt immunotherapy was needed. CONCLUSIONS: This disease has a rather favorable outcome provided that treatment is initiated early. However, resistance to first-line treatment, relapses, and long-term complications highlight the need to establish reliable biomarkers to distinguish different subtypes of this disorder to predict the clinical outcome and prognosis, and to refine management. |
format | Online Article Text |
id | pubmed-9644483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96444832022-11-15 Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature Karvigh, Sanaz Ahmadi Salehizadeh, Saeideh Vahabizad, Fahimeh J Med Case Rep Case Report BACKGROUND: Anti-leucine-rich glioma-inactivated 1 encephalitis is a newly emerged entity characterized by frequent faciobrachial dystonic seizures and a wide spectrum of subacute clinical symptoms such as other seizure types, mood and behavioral changes, and memory loss. We should be aware of differentiating this diagnosis from psychogenic nonepileptic seizures. Mesial temporal, limbic structures, and basal ganglia are the most commonly involved regions. CASE PRESENTATION: Here we review the available data, and report on two young Iranian (White) females, 24 and 18 years old, who represent distinct aspects of the disease. The clinical presentation and degree of tissue involvement varies to some extent in the two reported cases. Case 1 had prominent neuropsychiatric symptoms and suffered from frequent faciobrachial dystonic seizures with more significant basal ganglia involvement, whereas case 2 suffered from severe memory decline and dialeptic seizures along with mesial temporal involvement. Symptoms were refractory to usual treatment and prompt immunotherapy was needed. CONCLUSIONS: This disease has a rather favorable outcome provided that treatment is initiated early. However, resistance to first-line treatment, relapses, and long-term complications highlight the need to establish reliable biomarkers to distinguish different subtypes of this disorder to predict the clinical outcome and prognosis, and to refine management. BioMed Central 2022-11-09 /pmc/articles/PMC9644483/ /pubmed/36348436 http://dx.doi.org/10.1186/s13256-022-03650-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Karvigh, Sanaz Ahmadi Salehizadeh, Saeideh Vahabizad, Fahimeh Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature |
title | Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature |
title_full | Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature |
title_fullStr | Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature |
title_full_unstemmed | Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature |
title_short | Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature |
title_sort | anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644483/ https://www.ncbi.nlm.nih.gov/pubmed/36348436 http://dx.doi.org/10.1186/s13256-022-03650-x |
work_keys_str_mv | AT karvighsanazahmadi antileucinerichgliomainactivated1encephalitistwocasereportsandareviewoftheliterature AT salehizadehsaeideh antileucinerichgliomainactivated1encephalitistwocasereportsandareviewoftheliterature AT vahabizadfahimeh antileucinerichgliomainactivated1encephalitistwocasereportsandareviewoftheliterature |